Clinical Trials Logo

Citation(s)

First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma

Details for clinical trial NCT02649829